Both Mammoth’s therapies and diagnostics will be based on what the company touts as the largest toolbox of CRISPR proteins on earth. Through the financing, Mammoth plans to expand the toolbox and broaden its pipeline of genome-edited therapies, focusing on the smallest known CRISPR systems, based on Cas14, which targets single-stranded DNA; and Casɸ, which is encoded exclusively in the genomes of huge bacteriophages . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge